New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery.
New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery.
In the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab.
The Telegraph can reveal that UK Chancellor Rishi Sunak will announce a multi-billion-pound increase for the NHS in addition to the £36 billion packages.
Zak Mir takes a technical perspective on some of the most followed small caps on the London market. Today’s selection includes Carclo, Cloudcoco, Caerus, Condor, DeepVerge, Gulf Marine, Lukoil, Proton,
There were a couple of overnight broker notes and targets to chew on amongst a couple of the more high profile private investor stocks.
After a judge failed to meet a deadline, a decision in Hewlett Packard’s multi-billion-dollar case against Mike Lynch could be delayed until the end of the year.
The latest from Xtract Resources (XTR) takes us away from Bushranger as it announced the preliminary unaudited results for alluvial mining contractors for the Manica Concession for the three-month period
Zak Mir takes a charting look at some of the most followed small caps. Today’s selection includes e-Therapeutics, Egdon, Europa, Igas, Jersey, Jadestone, Longboat, Oilex, Pantheon, Roquefort, Skinbio, and Tiziana.
Fintech Group Mode Global (MODE) announce its unaudited results for the six months ended 30 June 2021. The company said it has built a strong platform of regulated and innovative
A flurry of activity in the markets this week, along with the most recent inflation data, Games Workshop, Keywords Studios, and Tullow Oil will also need to be updated.
On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the exploration and development of foralumab as a lymphodepletion agent to